What is HC Wainwright's Forecast for ACAD FY2027 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - HC Wainwright lifted their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a note issued to investors on Monday, May 19th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of $2.43 for the year, up from their prior estimate of $2.06. HC Wainwright has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.64 EPS and FY2029 earnings at $2.78 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business's revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 earnings per share.

ACAD has been the subject of a number of other research reports. StockNews.com cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, May 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday. Morgan Stanley increased their target price on shares of ACADIA Pharmaceuticals from $20.00 to $24.00 and gave the company an "equal weight" rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a "hold" rating and a $22.00 target price for the company. Finally, Mizuho increased their target price on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the company a "neutral" rating in a research report on Monday. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $25.75.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $21.69 on Wednesday. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $25.23. The firm has a 50-day moving average of $16.11 and a 200-day moving average of $17.19. The stock has a market cap of $3.63 billion, a PE ratio of 27.81 and a beta of 0.47.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC purchased a new position in ACADIA Pharmaceuticals during the 1st quarter valued at about $29,000. Banque Transatlantique SA purchased a new position in ACADIA Pharmaceuticals during the 1st quarter valued at about $31,000. Picton Mahoney Asset Management bought a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter valued at about $32,000. Federated Hermes Inc. boosted its position in shares of ACADIA Pharmaceuticals by 231.5% during the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 1,618 shares during the last quarter. Finally, Virtus Fund Advisers LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Activity

In other news, EVP Mark C. Schneyer sold 2,000 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, May 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the sale, the executive vice president now directly owns 62,130 shares in the company, valued at $1,553,250. The trade was a 3.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This trade represents a 21.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,994 shares of company stock worth $453,131 over the last 90 days. 26.50% of the stock is currently owned by corporate insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.